Gain Therapeutics, Inc.
Gain Therapeutics, Inc. (GANX) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · GANX · as of Sep 30, 2025
Ownership Breakdown
39
Institutional Holders
▲ 3 vs Q2
$7.70M
Total Inst. Value
▼ $4.15M vs Q2
42.65M
Shares Outstanding
freeFloat 97.63%
4.34M
13F Shares Held
▲ 553,803 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
GANX largest shareholders · institutional ownership
Q3 2025 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
JONES FINANCIAL COMPANIES LLLP pharmaceutical preparations | 676.8K | 2.23% | 2.23% | $1.21B | Nov 4, 2025 | ▼ 66 |
DME CAPITAL MANAGEMENT, LP pharmaceutical preparations | 566.1K | 1.87% | 1.87% | $1.00B | Nov 14, 2025 | — held |
VANGUARD GROUP INC pharmaceutical preparations | 534.4K | 1.76% | 1.76% | $945.80M | Nov 7, 2025 | — held |
CITADEL ADVISORS LLC pharmaceutical preparations | 373.6K | 1.23% | 1.23% | $661.20M | Nov 14, 2025 | ▲ 211.7K |
GEODE CAPITAL MANAGEMENT, LLC pharmaceutical preparations | 344.1K | 1.13% | 1.13% | $609.19M | Nov 12, 2025 | ▲ 53.7K |
CAMBRIDGE INVESTMENT RESEARCH ADVISORS, INC. pharmaceutical preparations | 318.6K | 1.05% | 1.05% | $564.00M | Nov 12, 2025 | ▲ 139.1K |
MARSHALL WACE, LLP pharmaceutical preparations | 175.1K | 57.71% | 57.71% | $309.94M | Nov 13, 2025 | ▼ 101.3K |
MORGAN STANLEY pharmaceutical preparations | 155.7K | 51.31% | 51.31% | $275.55M | May 27, 2026 | ▲ 79.2K |
UBS GROUP AG pharmaceutical preparations | 140.7K | 46.36% | 46.36% | $249.00M | Nov 13, 2025 | ▲ 108.0K |
RENAISSANCE TECHNOLOGIES LLC pharmaceutical preparations | 126.1K | 41.56% | 41.56% | $223.20M | Nov 13, 2025 | ▲ 32.1K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2025 vs prior quarter
Q3 2025
16
Increased
+741.0K shares8
New Positions
first time holders4
Decreased
−113.4K shares7
Sold Out
fully exitedNet shares change (top 50)
+627.6K
+741.0K / −113.4K
Net new holders
+13
8 new / 7 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
GANX insider trading · insider activity
Source: SEC Form 4
Insiders have been net buyers of shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
0
Sell transactions
0.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Mack Gene CEO, President | Mar 24, 2026 | Award | 200,000 | $1.86 | $372.0K | 200.0K | Form 4 ↗ |
Fuggetta Gianluca See Remark | Mar 24, 2026 | Award | 50,000 | $1.86 | $93.0K | 50.0K | Form 4 ↗ |
Islam Khalid director | Jun 24, 2025 | Award | 15,000 | $1.79 | $26.9K | 15.0K | Form 4 ↗ |
Nicaise Claude director | Jun 24, 2025 | Award | 15,000 | $1.79 | $26.9K | 15.0K | Form 4 ↗ |
Riley Jeffrey Scott director | Jun 24, 2025 | Award | 15,000 | $1.79 | $26.9K | 15.0K | Form 4 ↗ |
RICHMAN ERIC I director | Jun 24, 2025 | Award | 15,000 | $1.79 | $26.9K | 15.0K | Form 4 ↗ |
HASLER HANS PETER director | Jun 24, 2025 | Award | 15,000 | $1.79 | $26.9K | 15.0K | Form 4 ↗ |
GOLDSTEIN DOV A MD director | Jun 24, 2025 | Award | 15,000 | $1.79 | $26.9K | 15.0K | Form 4 ↗ |
Melincoff Gwen A director | Jun 24, 2025 | Award | 15,000 | $1.79 | $26.9K | 15.0K | Form 4 ↗ |
Fuggetta Gianluca See Remark | Mar 20, 2025 | Award | 50,000 | $2.29 | $114.5K | 50.0K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Gain Therapeutics, Inc. (GANX) is primarily owned by institutional investors, who hold approximately 10.2% of total shares outstanding. Company insiders own approximately 2.37%, while retail and public investors account for the remaining 87.46%.
The largest institutional shareholder of Gain Therapeutics, Inc. is JONES FINANCIAL COMPANIES LLLP, holding approximately 676,822 shares — equal to 2.23% of outstanding shares — as of September 30, 2025.
A total of 39 institutional investors currently hold GANX stock, with a combined institutional value of approximately $7,702,477 as of the most recent 13F filing period.
Frequently asked questions
GANX ownershipGain Therapeutics, Inc. (GANX) is primarily owned by institutional investors, who hold approximately 10.2% of shares. The largest shareholder is JONES FINANCIAL COMPANIES LLLP with a 2.23% stake. Company insiders hold 2.37%. Data sourced from SEC Form 13F as of September 30, 2025.